Financhill
Back

Genmab AS Quote, Financials, Valuation and Earnings

Genmab AS Price Quote

$22.76
+0.01 (+-0.07%)
(Updated: November 6, 2024 at 5:12 AM ET)

Genmab AS Key Stats

Sell
29
Genmab AS (GMAB) is a Sell

Day range:
$22.18 - $22.84
52-week range:
$22.18 - $32.89
Dividend yield:
0%
P/E ratio:
23.73
P/S ratio:
5.43
P/B ratio:
3.25%

Volume:
1.6M
Avg. volume:
1.2M
1-year change:
-21.79%
Market cap:
$14.4B
Revenue:
$2.4B
EPS:
$1.22

How Much Does Genmab AS Make?

  • How Much Are Genmab AS's Sales Annually?
    GMAB Revenues are $2.4B
  • How Much Profit Does Genmab AS's Make A Year?
    GMAB net income is $631.9M

Is Genmab AS Growing As A Company?

  • What Is Genmab AS's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 0.28%
  • What Is Genmab AS's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0.06%

Genmab AS Stock Price Performance

  • Did Genmab AS Stock Go Up Last Month?
    Genmab AS share price went down by -3.15% last month
  • Did GMAB's Share Price Rise Over The Last Year?
    GMAB share price fell by -21.79% over the past 1 year

What Is Genmab AS 52-Week High & Low?

  • What Is Genmab AS’s 52-Week High Share Price?
    Genmab AS has traded as high as $32.89 over the past 52 weeks
  • What Is Genmab AS’s 52-Week Low Share Price?
    Genmab AS has traded as low as $22.18 over the past 52 weeks

Genmab AS Price To Free Cash Flow

Is It Risky To Buy Genmab AS?

  • How Much Debt Does Genmab AS Have?
    Total long term debt quarterly is $0
  • How Much Cash Does Genmab AS Have?
    Cash and short term investments quarterly total is $2.3B
  • What Is Genmab AS’s Book Value Per Share?
    Book value per share is 7.00

Is Genmab AS Cash Flow Positive?

  • What Is GMAB Cash Flow From Operations?
    Cash flow from operations (TTM) is $971.7M
  • What Is Genmab AS’s Cash Flow From Financing?
    Cash flow from financing (TTM) is -$526M
  • What Is Genmab AS’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$1.4B

Genmab AS Return On Invested Capital

  • Is Management Doing A Good Job?
    GMAB return on invested capital is 17.81%
  • What Is Genmab AS Return On Assets?
    ROA measures how assets are converting to revenues and is 15.53%
  • What Is GMAB Return On Equity?
    ROE is a measure of profitability and is 17.81%

Genmab AS Earnings Date & Stock Price

  • What Is Genmab AS's Stock Price Today?
    A single share of GMAB can be purchased today for 22.75
  • What Is Genmab AS’s Stock Symbol?
    Genmab AS trades on the nasdaq under the ticker symbol: GMAB
  • When Is Genmab AS’s Next Earnings Date?
    The next quarterly earnings date for Genmab AS is scheduled on November 6, 2024
  • When Is GMAB's next ex-dividend date?
    Genmab AS's next ex-dividend date is November 6, 2024
  • How To Buy Genmab AS Stock?
    You can buy Genmab AS shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

Genmab AS Competitors

  • Who Are Genmab AS's Competitors?
    Below is a list of companies who compete with Genmab AS or are related in some way:
    • Ascendis Pharma AS (ASND)
    • Evaxion Biotech AS (EVAX)
    • Galecto Inc (GLTO)
    • IO Biotech Inc (IOBT)
    • Novo Nordisk AS (NVO)

Genmab AS Dividend Yield

  • What Is GMAB Dividend Yield?
    Genmab AS’s dividend yield currently is 0%
  • What Is Genmab AS’s Payout Ratio?
    Genmab AS’s payout ratio is 0%
  • When Did Genmab AS Last Pay A Dividend?
    The latest dividend pay date is November 6, 2024
  • What Is Genmab AS’s Dividend Per Share?
    Genmab AS pays a dividend of $0.00 per share

Genmab AS Analyst Estimates

YoY Growth Past Surprise
EPS: 5.68% 11.85%
Revenue: 27.97% 9.32%

Analyst Recommendations

Buy Recommendations: 2
Hold Recommendations: 5
Sell Recommendations: 0
Price Target: 38.11
Upside from Last Price: 67.52%

Major Shareholders

  • How many GMAB shares are owned by institutional investors?
    63.3M GMAB shares are owned by institutional investors
  • How many GMAB shares are owned by insiders?
    0 GMAB shares are owned by insiders